The association between glycogen synthase kinase 3 beta polymorphisms and Parkinson's disease susceptibility: A meta-analysis

Gene

Volumn 524, Issue 2, 2013, Pages 133-138

  Yuan, Yongsheng ^a   Tong, Qing ^a   Zhou, Xianju ^b   Zhang, Rui ^a   Qi, Zhiqiang ^c   Zhang, Kezhong ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c Jiangsu Shengze Hospital   (China)

Author keywords

Glycogen synthase kinase 3 beta; Meta analysis; Parkinson's disease; Polymorphisms

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA;

ARTICLE; CAUCASIAN; DNA POLYMORPHISM; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC MODEL; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; META ANALYSIS; PARKINSON DISEASE; POPULATION RESEARCH; PRIORITY JOURNAL; PROMOTER REGION; SENSITIVITY ANALYSIS;

ASIAN CONTINENTAL ANCESTRY GROUP; CONFIDENCE INTERVALS; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENETICS, POPULATION; GENOTYPE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; ODDS RATIO; PARKINSON DISEASE; PHOSPHORYLATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RISK FACTORS;

EID: 84878665519     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.04.045     Document Type: Article

References (33)

1. Chen G., Bower K.A., Ma C., Fang S., Thiele C.J., Luo J. Glycogen synthase kinase 3beta (GSK3beta) mediates 6-hydroxydopamine-induced neuronal death. FASEB J. 2004, 18:1162-1164.
2. Cochran W.G. The combination of estimates from different experiments. Biometrics 1954, 10:101-129.
3. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control. Clin. Trials 1986, 7:177-188.
4. Duka T., Duka V., Joyce J.N., Sidhu A. Alpha-synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models. FASEB J. 2009, 23:2820-2830.
5. Dun Y., et al. Inhibition of the canonical Wnt pathway by Dickkopf-1 contributes to the neurodegeneration in 6-OHDA-lesioned rats. Neurosci. Lett. 2012, 525:83-88.
6. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
7. Embi N., Rylatt D.B., Cohen P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur. J. Biochem. 1980, 107:519-527.
8. Evans W., et al. The tau H2 haplotype is almost exclusively Caucasian in origin. Neurosci. Lett. 2004, 369:183-185.
9. Forno L.S. Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 1996, 55:259-272.
10. Goris A., et al. Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann. Neurol. 2007, 62:145-153.
11. Haggerty T., et al. Hyperphosphorylated Tau in an alpha-synuclein-overexpressing transgenic model of Parkinson's disease. Eur. J. Neurosci. 2011, 33:1598-1610.
12. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002, 21:1539-1558.
13. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
14. Infante J., et al. Synergistic effect of two oxidative stress-related genes (heme oxygenase-1 and GSK3beta) on the risk of Parkinson's disease. Eur. J. Neurol. 2010, 17:760-762.
15. Jope R.S., Johnson G.V. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem. Sci. 2004, 29:95-102.
16. Kalinderi K., Fidani L., Katsarou Z., Clarimon J., Bostantjopoulou S., Kotsis A. GSK3beta polymorphisms, MAPT H1 haplotype and Parkinson's disease in a Greek cohort. Neurobiol. Aging 2011, 32(546):e1-e5.
17. Kozikowski A.P., et al. Highly potent and specific GSK-3beta inhibitors that block tau phosphorylation and decrease alpha-synuclein protein expression in a cellular model of Parkinson's disease. ChemMedChem 2006, 1:256-266.
18. Kwok J.B., et al. GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. Ann. Neurol. 2005, 58:829-839.
19. Lau K.F., Miller C.C., Anderton B.H., Shaw P.C. Molecular cloning and characterization of the human glycogen synthase kinase-3beta promoter. Genomics 1999, 60:121-128.
20. L'Episcopo F., et al. Plasticity of subventricular zone neuroprogenitors in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model of Parkinson's disease involves cross talk between inflammatory and Wnt/beta-catenin signaling pathways: functional consequences for neuroprotection and repair. J. Neurosci. 2012, 32:2062-2085.
21. Li Q., Michaud M., Canosa S., Kuo A., Madri J.A. GSK-3beta: a signaling pathway node modulating neural stem cell and endothelial cell interactions. Angiogenesis 2011, 14:173-185.
22. Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst 1959, 22:719-748.
23. Nagao M., Hayashi H. Glycogen synthase kinase-3beta is associated with Parkinson's disease. Neurosci. Lett. 2009, 449:103-107.
24. Rojo A.I., Sagarra M.R., Cuadrado A. GSK-3beta down-regulates the transcription factor Nrf2 after oxidant damage: relevance to exposure of neuronal cells to oxidative stress. J. Neurochem. 2008, 105:192-202.
25. Russ C., Lovestone S., Powell J.F. Identification of sequence variants and analysis of the role of the glycogen synthase kinase 3 beta gene and promoter in late onset Alzheimer's disease. Mol. Psychiatry 2001, 6:320-324.
26. Schapira A.H., Jenner P. Etiology and pathogenesis of Parkinson's disease. Mov. Disord. 2011, 26:1049-1055.
27. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur. J. Epidemiol. 2010, 25:603-605.
28. Van Den Eeden S.K., et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am. J. Epidemiol. 2003, 157:1015-1022.
29. Wider C., et al. SNCA, MAPT, and GSK3B in Parkinson disease: a gene-gene interaction study. Eur. J. Neurol. 2011, 18:876-881.
30. Wills J., Jones J., Haggerty T., Duka V., Joyce J.N., Sidhu A. Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia. Exp. Neurol. 2010, 225:210-218.
31. Yao L., et al. Activation of transcription factor MEF2D by bis(3)-cognitin protects dopaminergic neurons and ameliorates Parkinsonian motor defects. J. Biol. Chem. 2012, 287:34246-34255.
32. Zhang N., Yu J.T., Yang Y., Yang J., Zhang W., Tan L. Association analysis of GSK3B and MAPT polymorphisms with Alzheimer's disease in Han Chinese. Brain Res. 2011, 1391:147-153.
33. Zhao D.M., et al. GSK3beta reduces risk of sporadic Parkinson's disease in ethnic Chinese. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2012, 159B:718-721.